{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for vitamin root_modifications_structuralModifications_residueModified in root_modifications_structuralModifications_residueModified (approximate match)
Status:
US Approved Rx
(2018)
Source:
BLA761092
(2018)
Source URL:
First approved in 2018
Source:
BLA761092
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:survodutide [INN]
Source URL:
Class:
PROTEIN
Class:
PROTEIN
Pegorgotein (formerly known as PEG-SOD) was developed by Enzon pharmaceutical as a scavenger of oxygen-derived free radicals. This drug under the trade name DISMUTEC participated in phase III clinical trial in patients with a severe closed head injury. It was found that the drug failed to show a statistically significant difference between the treatment group and the control group. In spite of DISMUTEC exhibited longer circulating half-life and reduced immunogenicity; however, the drug showed insufficient therapeutic effect for this indication. In addition, pegorgotein was studied for patients with reperfusion injury and stroke. However, these studies were also discontinued.
Status:
Investigational
Source:
NCT02494154: Not Applicable Interventional Unknown status Respiratory Failure
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00996255: Phase 1 Interventional Terminated Advanced/Metastatic Solid Tumors
(2006)
Source URL:
Class:
PROTEIN
Targets:
Conditions:
PHA-793887 is an inhibitor of multiple cyclin dependent kinases (CDK) with activity against CDK2, CDK1 and CDK4. PHA-793887 was cytotoxic for leukemic cell lines in vitro, with IC(50) ranging from 0.3 to 7 uM. In colony assays PHA-793887 showed very high activity against leukemia cell lines, with an IC(50) <0.1 uM indicating that it has efficient and prolonged antiproliferative activity. PHA-793887 induced cell-cycle arrest, inhibited Rb and nucleophosmin phosphorylation. PHA-793887 has promising therapeutic activity against acute leukemias in vitro and in vivo.
